rRule 2.7, 3.10.3, 3.10.4, 3.10.5

### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

#### **BUREY GOLD LIMITED**

ABN

14 113 517 203

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

<sup>+</sup>Class of <sup>+</sup>securities issued or to be issued

Performance Rights

Number of \*securities issued or to be issued (if known) or maximum number which may be issued

17,000,000 Performance Rights

Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

**Performance Rights** – Each right can convert to an ordinary share, subject to satisfaction of specific vesting criteria and has an expiry date of 31 December 2017.

Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

If the additional +securities do not rank equally,

the date from which they do

please state:

the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment No

Performance rights have no dividend entitlements or voting rights and will only vest into ordinary shares if specified performance criteria are satisfied.

<sup>+</sup> See chapter 19 for defined terms.

5	Issue price or consideration	Nil
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	The issue of these incentive securities comprises part of the remuneration packages of senior personnel in the Burey Group, pursuant to shareholder approval on 26 November 2014.
6a	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections $6b - 6h$ in relation to the *securities the subject of this Appendix 3B, and comply with section $6i$	
(1)6b	The date the security holder resolution under rule 7.1A was passed	26 November 2014
(C)6c	Number of *securities issued without security holder approval under rule 7.1	Nil
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil
Ge Ge	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	17 million performance rights approved at the AGM on 26 November 2014
6f	Number of +securities issued under an exception in rule 7.2	N/A
6g	If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Refer attached Annexure 1
7	<sup>+</sup> Issue dates	17 December 2014
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	
	Cross reference: item 33 of Appendix 3B.	

<sup>+</sup> See chapter 19 for defined terms.

		Number	+Class
8	Number and <sup>+</sup> class of all <sup>+</sup> securities quoted on ASX ( <i>including</i> the <sup>+</sup> securities in section 2 if applicable)	575,368,925	Ordinary Shares
		·	
		Number	+Class
9	Number and <sup>+</sup> class of all <sup>+</sup> securities not quoted on ASX ( <i>including</i> the <sup>+</sup> securities in section 2 if applicable)	6,000,000	Options exercisable at \$0.08 cents each, expiring 6 February 2015
		6,000,000	Options exercisable at \$0.12 cents each, expiring 6 February 2015
		47,500,000	Options exercisable at \$0.05 on or before 31 December 2016
		17,000,000	Performance Rights expiring 31 December 2017
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	Performance ri	ghts have no entitlement to dividends.
		lot Applicab	ole
	Is security holder approval required?		
12	Is the issue renounceable or non-renounceable?		
13	Ratio in which the *securities will be offered		
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates		
15	<sup>+</sup> Record date to determine entitlements		
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?		
17	Policy for deciding entitlements in relation to fractions		

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B

#### New issue announcement

18	Names of countries in which the entity has security holders who will not be sent new offer documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
(a) 5 <sup>22</sup>	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do security holders sell their entitlements <i>in full</i> through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	
32	How do security holders dispose of their entitlements (except by sale through a broker)?	
33	<sup>+</sup> Issue date	

<sup>+</sup> See chapter 19 for defined terms.

#### Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34	Type of *securities (tick one)
(a)	+Securities described in Part 1
(b)	All other <sup>+</sup> securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
Entities	that have ticked box 34(a)
Addition	nal securities forming a new class of securities
Tick to in	dicate you are providing the information or documents
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories  1 - 1,000  1,001 - 5,000  5,001 - 10,000  10,001 - 100,000  100,001 and over
37	A copy of any trust deed for the additional *securities
Intities	that have ticked box 34(b)
38	Number of *securities for which *quotation is sought
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B

#### New issue announcement

40	Do the +securities rank equally in al respects from the +issue date with an existing +class of quoted +securities?
	If the additional *securities do no

If the additional \*securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Reason	for	request	for	quotation
now				

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another \*security, clearly identify that other \*security)

Number and +class of all +securities quoted on ASX (*including* the +securities in clause 38)

Number	+Class

#### Quotation agreement

<sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.

We warrant the following to ASX.

- The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.

<sup>+</sup> See chapter 19 for defined terms.

We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 17 December 2014
(Director/Company secretary)

Print name: Susmit Shah

== == == == ==

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15%	of capital	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid *ordinary securities on issue 12 months before tissue date or date of agreement to issue	the 354,219,003	
Add the following:		
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period under an exception in rule 7.2		
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period with shareholder approval – ratified by shareholders – 12/8/2014	55,070,92	
- shareholder approval – 12/8/2014	118,073,001	
Number of partly paid <sup>+</sup> ordinary securities that became fully paid in that month period	: 12	
Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3 which this form is annexed It may be useful to set out issues of securities on different dates as separate line items		
<b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during tha 12 month period	t	
"A"	525,368,925	
Step 2: Calculate 15% of "A"	,	
"B"	0.15	
	[Note: this value cannot be changed]	
<b>Multiply</b> "A" by 0.15	78,805,339	

<sup>+</sup> See chapter 19 for defined terms.

<b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in the 12 month period <i>not counting</i> those issued:	at
• Under an exception in rule 7.2	
Under rule 7.1A	
With security holder approval under rule 7.1 or rule 7.4	
Note:	
This applies to equity securities, unless specifically excluded – not	
just ordinary securities Include here (if applicable) the securities the subject of the Append	liv
3B to which this form is annexed	
It may be useful to set out issues of securities on different dates as separate line items	
" <b>C</b> "	
<i>rule 7.1</i> "A" x 0.15	78,805,3
"A" x 0.15 Note: number must be same as shown in Step 2	78,805,33
"A" x 0.15 Note: number must be same as shown in Step 2 Subtract "C"	78,805,33
"A" x 0.15 Note: number must be same as shown in Step 2 Subtract "C" Note: number must be same as shown in Step 3	
"A" x 0.15 Note: number must be same as shown in Step 2 Subtract "C"	78,805,33 78,805,33 [Note: this is the remaining placement capacity under rule 7.1]
"A" x 0.15 Note: number must be same as shown in Step 2 Subtract "C" Note: number must be same as shown in Step 3	78,805,33 [Note: this is the remaining placement
"A" x 0.15 Note: number must be same as shown in Step 2 Subtract "C" Note: number must be same as shown in Step 3  Total ["A" x 0.15] – "C"	78,805,33 [Note: this is the remaining placement capacity under rule 7.1]
"A" x 0.15 Note: number must be same as shown in Step 2 Subtract "C" Note: number must be same as shown in Step 3  Total ["A" x 0.15] – "C"	78,805,3: [Note: this is the remaining placement capacity under rule 7.1]
"A" x 0.15  Note: number must be same as shown in Step 2  Subtract "C"  Note: number must be same as shown in Step 3  Total ["A" x 0.15] – "C"  Part 2  Rule 7.1A – Additional placement capacity	78,805,3: [Note: this is the remaining placement capacity under rule 7.1]

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	525,368,925	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<b>Multiply</b> "A" by 0.10 52,536,		

<sup>+</sup> See chapter 19 for defined terms.

has been obtained

Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	50,000,000 shares	
Notes:  This applies to equity securities – not just ordinary securities  Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed  Do not include equity securities issued under rule 7.1 (they must be	(issued 26 November 2014)	

It may be useful to set out issues of securities on different dates as separate line items

E" 50,000,000

dealt with in Part 1), or for which specific security holder approval

# Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A "A" x 0.10 Note: number must be same as shown in Step 2 Subtract "E" Subtract "E" 50,000,000 Note: number must be same as shown in Step 3 Total ["A" x 0.10] – "E" 2,536,893 Note: this is the remaining placement capacity under rule 7.1A

<sup>+</sup> See chapter 19 for defined terms.